Pioglitazone inhibits the expression of matrix metalloproteinase-9, a protein involved in diabetes-associated wound healing

Molecular Medicine Reports

Volumn 10, Issue 2, 2014, Pages 1084-1088

  Zhang, Jun ^a   Huang, Xiaoyuan ^a   Wang, Lingfeng ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Baotou Steel Group Company   (China)

Author keywords

Diabetes; Matrix metalloproteinase 9; Pioglitazone; Wound healing

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; GELATINASE B; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN;

ARTICLE; CELL DENSITY; CELL VIABILITY; CULTURE MEDIUM; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KERATINOCYTE; MTT ASSAY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING; ANIMAL; BOVINAE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; CATTLE; CELL LINE; CELL SURVIVAL; DIABETES COMPLICATIONS; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MATRIX METALLOPROTEINASE 9; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; THIAZOLIDINEDIONES; WOUND HEALING;

EID: 84903269312     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2277     Document Type: Article

References (25)

1. Gill SE and Parks WC: Metalloproteinases and their inhibitors: regulators of wound healing. Int J Biochem Cell Biol 40: 1334-1347, 2008.
2. Yang C, Zhu P, Yan L, et al: Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. J Am Podiatr Med Assoc 99: 489-496, 2009.
3. Reiss MJ, Han YP, Garcia E, et al: Matrix metalloproteinase-9 delays wound healing in a murine wound model. Surgery 147: 295-302, 2010.
4. Liu Y, Min D, Bolton T, et al: Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care 32: 117-119, 2009.
5. Rayment EA, Upton Z and Shooter GK: Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br J Dermatol 158: 951-961, 2008. (Pubitemid 351521431)
6. Bell DS: Beta-cell rejuvenation with thiazolidinediones. Am J Med 115: 20S-23S, 2003.
7. Saitoh Y, Chun-ping C, Noma K, Ueno H, Mizuta M and Nakazato M: Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta cells. Diabetes Obes Metab 10: 564-573, 2008. (Pubitemid 351850900)
8. Liu X, Luo D, Zheng M, Hao Y, Hou L and Zhang S: Effect of pioglitazone on insulin resistance in fructose-drinking rats correlates with AGEs/RAGE inhibition and block of NADPH oxidase and NF kappa B activation. Eur J Pharmacol 629: 153-158, 2010.
9. Ao C, Huo Y, Qi L, Xiong Z, Xue L and Qi Y: Pioglitazone suppresses the lipopolysaccharide-induced production of inflammatory factors in mouse macrophages by inactivating NF-kappaB. Cell Biol Int 34: 723-730, 2010.
10. Wan H, Yuan Y, Qian A, Sun Y and Qiao M: Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells. Biomed Pharmacother 62: 466-472, 2008.
11. Bell DS: Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgrad Med 8: 35-44, 2003.
12. Gumieniczek A, Hopkała H and Zabek A: Protective effects of a PPARgamma agonist pioglitazone on anti-oxidative system in testis of diabetic rabbits. Pharmazie 63: 377-378, 2008. (Pubitemid 351744521)
13. Collino M, Aragno M, Mastrocola R, et al: Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 530: 70-80, 2006. (Pubitemid 43037126)
14. Gumieniczek A, Krzywdzińska M and Nowak M: Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide. Exp Lung Res 35: 371-379, 2009.
15. Somi MH, Hajipour B, Asl NA, et al: Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. Transplant Proc 41: 4105-4109, 2009.
16. Bernardo A, Bianchi D, Magnaghi V and Minghetti L: Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells. J Neuropathol Exp Neurol 68: 797-808, 2009.
17. Fukami K, Yamagishi SI, Sakai K, Kaida Y, Adachi T, Ando R and Okuda S: Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis. Rejuvenation Res 16: 460-466, 2013.
18. Goldin A, Beckman JA, Schmidt AM and Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605, 2006. (Pubitemid 44199649)
19. Bierhaus A and Nawroth PP: Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52: 2251-2263, 2009.
20. Wautier JL and Guillausseau PJ: Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 27: 535-542, 2001. (Pubitemid 33051702)
21. Yonutas HM and Sullivan PG: Targeting PPAR isoforms following CNS injury. Curr Drug Targets 14: 733-742, 2013.
22. Pan HW, Xu JT and Chen JS: Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production. Mol Biol Rep 38: 4501-4508, 2011.
23. Dong X, Geng Z, Zhao Y, Chen J and Cen Y: Involvement of mast cell chymase in burn wound healing in hamsters. Exp Ther Med 5: 643-647, 2013.
24. Da Silva Morais A, Abarca-Quinones J, Horsmans Y, Stärkel P and Leclercq IA: Peroxisome proliferated-activated receptor gamma ligand, Pioglitazone, does not prevent hepatic fibrosis in mice. Int J Mol Med 19: 105-112, 2007.
25. Lahiri S, Sen T and Palit G: Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Eur J Pharmacol 609: 118-125, 2009.